ATE452183T1 - Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren - Google Patents

Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren

Info

Publication number
ATE452183T1
ATE452183T1 AT99960336T AT99960336T ATE452183T1 AT E452183 T1 ATE452183 T1 AT E452183T1 AT 99960336 T AT99960336 T AT 99960336T AT 99960336 T AT99960336 T AT 99960336T AT E452183 T1 ATE452183 T1 AT E452183T1
Authority
AT
Austria
Prior art keywords
yields
serum
producing
cell culture
improved
Prior art date
Application number
AT99960336T
Other languages
English (en)
Inventor
Shuyuan Zhang
Capucine Thwin
Zheng Wu
Toohyon Cho
Shawn Gallagher
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22752406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE452183(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE452183T1 publication Critical patent/ATE452183T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cleaning And De-Greasing Of Metallic Materials By Chemical Methods (AREA)
  • Cleaning By Liquid Or Steam (AREA)
AT99960336T 1998-12-01 1999-11-16 Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren ATE452183T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/203,078 US7732129B1 (en) 1998-12-01 1998-12-01 Method for the production and purification of adenoviral vectors
PCT/US1999/026966 WO2000032754A1 (en) 1998-12-01 1999-11-16 An improved method for the production and purification of adenoviral vectors

Publications (1)

Publication Number Publication Date
ATE452183T1 true ATE452183T1 (de) 2010-01-15

Family

ID=22752406

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960336T ATE452183T1 (de) 1998-12-01 1999-11-16 Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren

Country Status (10)

Country Link
US (3) US7732129B1 (de)
EP (1) EP1135469B1 (de)
AT (1) ATE452183T1 (de)
AU (1) AU775579B2 (de)
CA (1) CA2353787C (de)
DE (1) DE69941823D1 (de)
DK (1) DK1135469T3 (de)
ES (1) ES2338288T3 (de)
PT (1) PT1135469E (de)
WO (1) WO2000032754A1 (de)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100503701B1 (ko) * 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US6168941B1 (en) 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US20020064860A1 (en) * 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
EP1453536A4 (de) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd Zusammensetzung zur konservierung von viren
AU2003268210A1 (en) * 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US7229554B2 (en) * 2002-09-25 2007-06-12 Novo Nordisk A/S Purification process comprising microfiltration at elevated temperatures
WO2004099396A1 (en) * 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
AU2005214090B2 (en) * 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
JP2008501339A (ja) * 2004-06-01 2008-01-24 ジェンザイム・コーポレイション Ａａｖベクターの凝集を防ぐための組成物およびその方法
CA2586107A1 (en) * 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
US20060223053A1 (en) * 2004-11-09 2006-10-05 Roper D K Direct measurement of sorption on three-dimensional surfaces such as resins, membranes or other preformed materials using lateral dispersion to estimate rapid sorption kinetics or high binding capacities
ES2716874T3 (es) 2005-03-23 2019-06-17 Genmab As Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
CN101155915B (zh) * 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
SE528214C2 (sv) * 2005-06-23 2006-09-26 Proliff Ab Förfarande för framställning av blodplättslysat
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US9278159B2 (en) 2005-07-22 2016-03-08 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US20090093403A1 (en) 2007-03-01 2009-04-09 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
US10052497B2 (en) * 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9198984B2 (en) 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008101128A1 (en) * 2007-02-14 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
US10035027B2 (en) * 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
EP2612868B1 (de) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunsuppressive Polypeptide und Nucleinsäuren
JP5801188B2 (ja) 2008-04-23 2015-10-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的細胞を光刺激するためのシステム、方法、および組成物
MX2010012986A (es) * 2008-05-29 2011-05-25 Univ Leland Stanford Junior Linea de celulas, sistema y metodo para control optico de mensajeros secundarios.
SG191593A1 (en) 2008-06-17 2013-07-31 Univ Leland Stanford Junior Methods, systems and devices for optical stimulation of target cells using an optical transmission element
MY162929A (en) * 2008-06-17 2017-07-31 Univ Leland Stanford Junior Apparatus and methods for controlling cellular development
WO2010006049A1 (en) * 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
WO2010019619A1 (en) * 2008-08-11 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior Univeristy Method and composition for controlling gene expression
ES2532015T3 (es) * 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
AU2014240246B2 (en) * 2008-12-05 2017-08-10 Takeda Vaccines, Inc. Compositions, methods and uses for inducing viral growth
SG10202007719TA (en) * 2008-12-05 2020-09-29 Takeda Vaccines Inc Compositions, methods and uses for inducing viral growth
EP3159405B8 (de) 2010-01-05 2018-11-07 Vascular Biogenics Ltd. Verfahren zur verwendung eines spezifischen adenovirenmittels gegen angiogenese
WO2011097447A2 (en) * 2010-02-04 2011-08-11 Neurologix, Inc. Production of recombinant virus
US20120315696A1 (en) * 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
JP5866332B2 (ja) 2010-03-17 2016-02-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 感光性イオンを通過させる分子
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
AU2011323228B2 (en) 2010-11-05 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of memory function
CA2816990A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
CA2816971A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
WO2012061684A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Upconversion of light for use in optogenetic methods
EP2635346B1 (de) 2010-11-05 2017-03-29 The Board of Trustees of the Leland Stanford Junior University Optogenetische steuerung eines verhaltens in zusammenhang mit belohnungen
CN106106368A (zh) 2010-11-05 2016-11-16 斯坦福大学托管董事会 光控cns功能障碍
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
AU2011336410B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Lyophilized viral formulations
EP2780034A1 (de) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
WO2013090356A2 (en) 2011-12-16 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
CA2865296A1 (en) 2012-02-21 2013-08-29 Karl A. DEISSEROTH Compositions and methods for treating neurogenic disorders of the pelvic floor
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
EP2968997B1 (de) 2013-03-15 2019-06-26 The Board of Trustees of the Leland Stanford Junior University Optogenetische steuerung des verhaltenszustandes
MX361774B (es) 2013-04-25 2018-12-17 Janssen Vaccines & Prevention Bv Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
CN105431046B (zh) 2013-04-29 2020-04-17 小利兰·斯坦福大学托管委员会 用于靶细胞中的动作电位的光遗传学调节的装置、系统和方法
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
WO2015023782A1 (en) 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (de) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passives ersetzen von medien
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
WO2016049110A1 (en) 2014-09-25 2016-03-31 Cold Spring Harbor Laboratory Treatment of rett syndrome
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
RU2020109343A (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
DK3218386T3 (da) 2014-11-14 2021-06-07 Voyager Therapeutics Inc Modulatorisk polynukleotid
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
EP3230441A4 (de) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
EP3368054A4 (de) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Regulierbare expression unter verwendung des adeno-assoziierten virus (aav)
WO2017160360A2 (en) 2015-12-11 2017-09-21 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
EP4215605A1 (de) 2015-12-11 2023-07-26 The Trustees of The University of Pennsylvania Skalierbares reinigungsverfahren für aav8
WO2017100704A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109831916B (zh) 2016-05-18 2023-07-21 沃雅戈治疗公司 治疗亨廷顿氏舞蹈病的组合物和方法
IL302748A (en) 2016-05-18 2023-07-01 Voyager Therapeutics Inc modulatory polynucleotides
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3831281A1 (de) 2016-08-30 2021-06-09 The Regents of The University of California Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
US10626376B2 (en) * 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
RU2663132C1 (ru) * 2017-01-31 2018-08-01 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Способ получения низкомолекулярной днк высокой степени чистоты
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (de) 2017-03-31 2020-05-27 Terumo BCT, Inc. Zellexpansion
WO2018191313A1 (en) * 2017-04-10 2018-10-18 Epicentrx, Inc. Method for producing recombinant virus
JP2020517238A (ja) * 2017-04-18 2020-06-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アデノ随伴ウイルスベクターの産生方法
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
EP3624844A1 (de) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
EP3662060A2 (de) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur aav-freisetzung
EP3681533A1 (de) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Verfahren zur sicheren induktion der immunität gegen rsv
WO2019060629A1 (en) 2017-09-21 2019-03-28 Codiak Biosciences, Inc. PRODUCTION OF EXTRACELLULAR VESICLES IN A SUSPENSION OF INSULATED CELLS USING CHEMICALLY DEFINED CELL CULTURE MEDIA
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症（ａｌｓ）の治療
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
AU2019205330A1 (en) 2018-01-04 2020-08-27 Iconic Therapeutics Llc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
EP3762500A1 (de) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
JP2021529513A (ja) 2018-07-02 2021-11-04 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症および脊髄に関連する障害の治療
US20210355454A1 (en) 2018-07-24 2021-11-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
AU2020208467A1 (en) 2019-01-18 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing AAV particles
TW202106879A (zh) 2019-04-29 2021-02-16 美商航海家醫療公司 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
CN114173827A (zh) * 2019-06-28 2022-03-11 武田药品工业株式会社 腺相关病毒纯化方法
CN110257467A (zh) * 2019-07-22 2019-09-20 福州市皮肤病防治院 一种检测肿瘤抑制因子p53显性抑制突变的试剂盒及其应用
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN115552020A (zh) * 2020-05-14 2022-12-30 默克专利股份公司 用于纯化腺相关病毒颗粒或腺病毒的方法和组合物
EP4192514A1 (de) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
EP4225382A2 (de) 2020-10-07 2023-08-16 Asklepios Biopharmaceutical, Inc. Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
RU2745307C1 (ru) * 2020-12-01 2021-03-23 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Способ очистки рекомбинантного аденовируса 26 серотипа (Ad26)
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2023187691A1 (en) * 2022-03-30 2023-10-05 Csl Behring Llc Methods of purifying an enveloped virus
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5106841A (en) * 1986-05-13 1992-04-21 Chai-Tech Corporation Antiviral compositions and method for their use
EP0273085A1 (de) 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
JPH0761955B2 (ja) 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
US5219752A (en) * 1988-05-25 1993-06-15 Teijin, Limited Process for continuously culturing adherent animal cells
IT1238231B (it) 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
NO312681B1 (no) 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
DK0713397T3 (da) 1992-03-24 2003-03-31 United Cancer Res Inst Vaccine indeholdende levende virus
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
EP0672137A1 (de) 1992-09-18 1995-09-20 CANJI, Inc. Gentherapie durch einen retroviralen vektor mit einem tumorunterdrückenden gen
EP0682697A4 (de) 1993-01-29 1997-07-30 New Brunswick Scientific Co Methode und gerät zur verankerung und suspension von zellkulturen.
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
AU7971194A (en) 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
CA2181066A1 (en) 1994-01-12 1995-07-20 Hitoshi Kotani Purification of retroviral vectors
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
AU2127395A (en) 1994-03-22 1995-10-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Highly efficient production and isolation of viral particles
AU3551195A (en) 1994-09-23 1996-04-09 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5744304A (en) 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
EP0841942B2 (de) 1995-08-01 2007-12-12 Sanofi Pasteur Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
EP0847442A1 (de) 1995-08-30 1998-06-17 Genzyme Corporation Chromatographische reinigung von adenoviren und aav
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
IL127692A0 (en) * 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
ATE477320T1 (de) 1996-12-13 2010-08-15 Schering Corp Methoden zur virus-reinigung
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
CA2282683A1 (en) 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
GB9711130D0 (en) 1997-05-29 1997-07-23 Kvaerner Process Systems As Multi-phase separation
US6026667A (en) * 1997-06-02 2000-02-22 Topy Kogyo Kabushiki Kaisha Apparatus for manufacturing a one end flange-less wheel rim
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
BR9908015A (pt) 1998-02-17 2001-04-24 Schering Corp Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
AU756889B2 (en) 1998-04-22 2003-01-23 Genvec, Inc. Efficient purification of adenovirus
US5965358A (en) 1998-08-26 1999-10-12 Genvec, Inc. Method for assessing the relative purity of viral gene transfer vector stocks
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
CZ20012428A3 (cs) 1998-12-31 2001-11-14 Aventis Pharma S. A. Způsob separace virových částic
US6082628A (en) * 1999-05-14 2000-07-04 Board Of Trustees Of The University Of Arkansas Powder charger and sprayer
US6316185B1 (en) 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
JP2002054561A (ja) 2000-08-08 2002-02-20 Toyota Industries Corp 容量可変型圧縮機の制御弁及び容量可変型圧縮機
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
DE10050114A1 (de) 2000-10-09 2002-04-25 Wolf Gmbh Richard Verwendung einer Gelmasse

Also Published As

Publication number Publication date
AU1723400A (en) 2000-06-19
US7732129B1 (en) 2010-06-08
CA2353787C (en) 2011-12-20
US7125706B2 (en) 2006-10-24
PT1135469E (pt) 2010-03-23
WO2000032754A1 (en) 2000-06-08
US20020182723A1 (en) 2002-12-05
EP1135469B1 (de) 2009-12-16
DE69941823D1 (de) 2010-01-28
DK1135469T3 (da) 2010-04-12
AU775579B2 (en) 2004-08-05
CA2353787A1 (en) 2000-06-08
EP1135469A1 (de) 2001-09-26
ES2338288T3 (es) 2010-05-05
US20080050770A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
ATE452183T1 (de) Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren
NO992389D0 (no) Forbedret fremgangsmÕte for fremstilling og rensning av adenovirale vektorer
Hercyk et al. The vesicular stomatitis virus L protein possesses the mRNA methyltransferase activities
ES2349046T3 (es) Métodos para purificar virus.
de las Mercedes Segura et al. A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography
DE60032586D1 (de) Zusammensetzungen und verfahren zur herstellung von helfer-freien rekombinanten adeno-assoziierten viren
JP2008518632A5 (de)
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
PT862643E (pt) Funcoes acessorias para utilizacao na producao de virioes de aav recombinantes
HUP0100670A2 (hu) Vírusokat tartalmazó készítmények és eljárások víruspreparátumok töményítésére
ATE414146T1 (de) Methoden zur herstellung von helpervirusfreien präparationen von freien rekombinenten aav- vektoren mit hohem titer
CA2955877A1 (en) Process for the purification of poliovirus from cell cultures
US9868762B2 (en) Method for purifying virus-like particles (VLP)
CN103215308A (zh) 表达重组人fviii的整合质粒、细胞株及其构建方法和应用
ATE369430T1 (de) Methoden zur herstellung von nukleotidintegrasen
SK22695A3 (en) Isolation and purification method of proteins dependent from vitamin k
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
CN109153978A (zh) 使用聚二烯丙基二烷基铵盐分离腺相关病毒的方法
CA2501220A1 (en) Vaccines against west nile virus
ATE266094T1 (de) Produktion des proteins ingap mit hoher expressionsrate
CA2289776A1 (en) An infectious clone for human parainfluenza virus type 3
Pelz et al. Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus
WO1999052947A3 (en) TRANSFERRIN RECEPTOR GENES OF $i(MORAXELLA)
Kongsvik et al. Subfractionation of CsCI-purified H-1 parvovirus on metrizamide gradients
Patton Transcription of the bovine parvovirus genome.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1135469

Country of ref document: EP